UK Regulatory Changes During A Brexit Transition Period

UK Regulatory Changes During A Brexit Transition Period – The Government Explains All

Guidance documents on the regulation of medicines in the UK during a Brexit transition period have been published by the government, covering areas like batch release, drug approvals, and the role of the UK MHRA in the EU regulatory system.

Changes ahead — The UK government is trying to explain what will happen to regulation during a Brexit transition period

The UK government has issued a number of guidance documents in an attempt to clarify what is likely to happen to life sciences regulation during any Brexit transition period following the UK’s departure from the EU at the end of March 2019.

The documents, which update and expand on the government’s earlier advice on the regulatory implications of Brexit, cover topics such...